LabCorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.
To diagnose a Zika virus infection
When you develop a fever, rash, joint pain, and conjunctivitis (pink eye) after traveling to an area where Zika virus is endemic or have symptoms and had sexual contact with someone who recently traveled from an area where Zika is present; if you are pregnant and have traveled to an area where Zika is active, regardless of symptoms; or when a baby is born with microcephaly (small head)
A blood sample drawn from a vein in your arm and/or a urine sample collected in a clean container; less commonly cerebrospinal fluid (CSF) or amniotic fluid
Zika is a viral infection that is spread primarily by the bites of infected Aedes mosquitoes and less commonly by sexual transmission. Testing detects the genetic material (RNA) of the Zika virus in blood, urine, cerebrospinal fluid (CSF), or amniotic fluid or detects antibodies in the blood produced in response to Zika virus infection.
About 80% of individuals infected with Zika virus will have no symptoms at all, while others will have only mild illness. For people who do develop symptoms, prognosis is very good for full recovery. The most common initial symptoms of Zika include fever, rash, joint pain, and conjunctivitis (pink eye) lasting from a few days to a week. These symptoms are similar to other mosquito-borne illnesses like dengue fever and chikungunaya. The similarities between Zika symptoms and other diseases mean that laboratory testing is essential to diagnosing Zika virus.
Zika virus infection is typically diagnosed with blood and urine tests. Laboratory tests may include either molecular tests for Zika virus (PCR), which detect the presence of the virus itself, or an antibody test that detects antibodies produced by the immune system after a person has been exposed to the virus.
Since the first human case of Zika virus in 1952, outbreaks have been reported in Africa, Southeast Asia, and the Pacific Islands. Zika was found in Brazil in May 2015, representing the virus' first introduction to the Americas. Since then, it has rapidly spread through the Americas. Check the Centers for Disease Control and Prevention (CDC) web page for updates and more information about Zika virus status in the U.S.
While most people infected with the Zika virus do not develop noticeable or severe symptoms, it can cause risk of serious complications for a pregnant woman and her unborn child, including miscarriage and birth defects. Starting in May 2015, Brazilian health officials reported an increase in Zika infections along with an uptick in babies born with microcephaly (smaller than expected heads). Since the outbreak that started in Brazil, the CDC has confirmed that Zika virus infection during pregnancy can cause severe microcephaly and other birth defects.
Babies with microcephaly have much smaller heads than normal and severe microcephaly causes a range of lifelong problems, including developmental disabilities, seizures, hearing loss, and vision loss. Scientists are still learning about other impacts of Zika infection during pregnancy. If you are pregnant or considering pregnancy, the CDC web page has up-to-date recommendations on how to protect yourself.
In rare cases, Zika virus is also linked to the development of Guillain-Barré syndrome (GBS). GBS is an autoimmune disorder that causes the body to attack its own nervous system, causing muscle weakness and paralysis. Researchers are still working to understand what causes GBS, but most people with GBS develop it after a viral or bacterial infection. The CDC is still investigating the relationship between Zika and GBS.
In January 2016, the CDC issued a travel alert for areas of the world where Zika virus is circulating. The alert recommends that pregnant women avoid travel to certain areas with Zika, and that women considering pregnancy consult their healthcare providers before traveling to those areas. There is currently no vaccine or treatment for Zika virus. Avoiding Aedes mosquito bites is the best way to prevent a Zika infection.
Since information about Zika is changing quickly, check the CDC's web site for the latest on the virus.
A blood sample is collected by inserting a needle into a vein in the arm. A urine sample is collected by voiding into a clean container. Sometimes, a healthcare practitioner may collect a sample of cerebrospinal fluid or amniotic fluid.
No test preparation is needed.
Zika virus testing is used to detect a Zika infection in a person without signs and symptoms and to determine whether a person with signs and symptoms of Zika has been infected after exposure in a region with Zika virus. It may also be used to test people who have had sexual contact with a recent traveler to a country with Zika.
Zika infection may be difficult to diagnose without laboratory tests because symptoms may resemble those of other diseases, such as dengue fever or chikungunya infection, or the patient may be asymptomatic. Currently, two types of testing are available:
Molecular tests of blood are not likely to detect Zika after 7 days of illness. Urine testing can detect Zika RNA for at least two weeks after symptoms begin. According to a recent study, urine may be the preferred specimen for detecting Zika RNA during the first three weeks of illness. If urine and blood specimens are taken less than 7 days after the onset of illness, the Centers for Disease Control and Prevention (CDC) recommends testing both samples.
If the result of a PCR test is negative, an antibody test can be used to help establish a diagnosis, according to the CDC (see below).
IgM antibody tests can be positive if a person has been infected with a similar virus, such as dengue (called cross-reaction). If an initial IgM antibody test is positive, a second test called the Plaque Reduction Neutralization Test (PRNT) is used to confirm the presence of antibodies to Zika virus and to help rule out other viral infections.
The amount of time that it takes for test results to become available can vary depending on where the person being tested is located and whether the state public health laboratory is performing Zika testing. Some samples may need to be sent to the CDC for testing. In general, it may take about three weeks for results, according to the CDC.
Zika testing may be ordered when an individual has signs and symptoms associated with Zika infection and recently traveled to areas where the virus is actively spread by mosquitos or had sexual contact with someone who recently traveled from an area where Zika is present.
Signs and symptoms of Zika typically last between 2 and 7 days. Some of the main signs and symptoms include:
According to CDC guidelines, asymptomatic pregnant women who have recently traveled to an area with active Zika transmission may be offered the antibody test. Pregnant women who have had sexual contact with a recent traveler to a country with Zika may also be tested.
Testing may be performed when a newborn has microcephaly (an abnormally small head). If a person has Guillain-Barre syndrome and is at risk for Zika virus, that person may be tested.
Since information about Zika is changing quickly, check the CDC's web site for the latest on the virus and testing.
Tests for the Zika virus or antibodies do not provide any information about fetal health in pregnant women with Zika virus.
Physical symptoms like rash or aching joints are not a reliable means for diagnosing Zika because the symptoms are not specific to Zika.
The U.S. Food and Drug Administration (FDA) has directed blood collection facilities to screen all donated blood and blood components for the Zika virus. The FDA approved two investigational tests for this purpose. The tests were approved under an "investigational new device (IND)" protocol and did not go through the standard regulatory process prior to implementation, which can be time-consuming. The tests screen for the presence of the virus by detecting its genetic material (RNA). Units of blood that test positive for the virus are removed from the supply and not used for transfusions.
The amount of time that it takes for results to become available can vary depending on where you are located and whether your local or state public health laboratory is performing Zika testing. Some samples may need to be sent to the Centers for Disease Control and Prevention (CDC) for testing. Test results may be available within 3 weeks. However, it may take longer during the summer when arbovirus (viruses spread by bites of mosquitos and ticks) activity is high.
Yes. It can be spread from a pregnant woman to her developing baby. In rare cases, it can be spread from person-to-person through sexual contact. The CDC recommends that until more is known about Zika and pregnancy, pregnant women use condoms with male sexual partners who have lived or traveled to areas with Zika. In rare cases, Zika may be transmitted through blood transfusion or organ donation. Health officials are still investigating reports of Zika transmission via blood transfusion in Brazil.
Currently, there is no Zika vaccine available and no treatment for the virus. Limiting exposure to the virus primarily depends upon protecting against mosquito bites. To avoid mosquito bites:
Since Zika can be spread through sexual contact, you can help protect yourself by using a condom correctly and consistently when you have sex. The only way to be sure to avoid getting Zika through sexual contact is by abstaining from sex.
If you've been infected with Zika once, it's unlikely that you will be infected again.
(2016 January 15). Press release: CDC issues interim travel guidance related to Zika virus for 14 countries and territories in central and South America and the Caribbean. Centers for Disease Control and Prevention. Available online at http://www.cdc.gov/media/releases/2016/s0315-zika-virus-travel.html. Accessed 5/17/2016.
Petersen, E., et al. (2016 January 22) Interim guidelines for pregnant women during a Zika virus outbreak — United States, 2016. Centers for Disease Control and Prevention. Available online at http://www.cdc.gov/mmwr/volumes/65/wr/mm6502e1.htm. Accessed 5/17/2016.
(2016 February 16). Centers for Disease Control and Prevention Zika MAC- ELISA emergency use authorization fact sheet for health care providers: Interpreting Zika MAC - ELISA results. Centers for Disease Control and Prevention. Available online at http://www.cdc.gov/zika/pdfs/zika-mac-elisa-fact-sheet-for-hcp.pdf. Accessed 5/17/2016.
(2016 March 18). Press release: New CDC laboratory test for Zika virus authorized for emergency use by FDA. Centers for Disease Control and Prevention. Available online at http://www.cdc.gov/media/releases/2016/s0318-zika-lab-test.html. Accessed 5/17/2016.
(2016 March 23). Laboratory testing for Zika virus infection, interim guidance. World Health Organization. Available online at http://apps.who.int/iris/bitstream/10665/204671/1/WHO_ZIKV_LAB_16.1_eng.pdf. Accessed 5/17/2016.
(2016 March 29). Guillain-Barré syndrome – Panama. World Health Organization. Available online at http://www.who.int/csr/don/29-march-2016-gbs-panama/en/. Accessed 5/17/2016.
(Updated 2016 April 14). Zika and Guillain-Barré Syndrome. Centers for Disease Control and Prevention. Available online at www.cdc.gov/zika/about/gbs-qa.html. Accessed 5/17/2016.
(2016 April 15). U.S. health experts debate advice to women once Zika virus arrives. MedlinePlus. Available online at https://www.nlm.nih.gov/medlineplus/news/fullstory_158335.html. Accessed 5/17/2016.
(Updated 2016 April 15). Zika virus. World Health Organization. Available online at http://www.who.int/mediacentre/factsheets/zika/en/. Accessed 5/17/2016.
(Updated 2016 April 27). Zika and blood transfusion. Centers for Disease Control and Prevention. Available online at http://www.cdc.gov/zika/transmission/blood-transfusion.html. Accessed 5/17/2016.
(Updated 2016 April 26). Symptoms, diagnosis and treatment. Centers for Disease Control and Prevention. Available online at http://www.cdc.gov/zika/symptoms/index.html. Accessed 5/17/2016.
(Updated, 2016 April 29). Zika and pregnancy. Centers for Disease Control and Prevention. Available online at http://www.cdc.gov/zika/pregnancy/index.html. Accessed 5/17/2016.
(Updated 2016 May 4). Zika and other emerging viruses transmitted by the Aedes mosquito. Quest Diagnostics. Available online at http://education.questdiagnostics.com/faq/FAQ178. Accessed 5/17/2016.
(Updated 2016 May 9). Areas with Zika. Centers for Disease Control and Prevention. Available online at http://www.cdc.gov/zika/geo/. Accessed 5/17/2016.
(2016 May 10). Centers for Disease Control and Prevention. Interim Guidance for Zika Virus Testing of Urine — United States, 2016. Available online at http://www.cdc.gov/mmwr/volumes/65/wr/mm6518e1.htm?s_cid=mm6518e1_w . Accessed 5/17/2016
(2016 May 11). Zika symptoms may vary, so testing is crucial. MedlinePlus. Available online athttps://www.nlm.nih.gov/medlineplus/news/fullstory_158783.html. Accessed 5/17/2016.
(Updated, 2016 May 13) Food and Drug Administration. Zika Virus Emergency Use Authorization. Available online at http://www.fda.gov/medicaldevices/safety/emergencysituations/ucm161496.htm. Accessed 5/17/2016.
Bingham, A.M., et al. (2016 May 13). Comparison of test results for Zika virus RNA in urine, serum, and saliva specimens from persons with travel-associated Zika Virus disease — Florida, 2016. Available online at http://www.cdc.gov/mmwr/volumes/65/wr/mm6518e2.htm. Accessed 5/17/2016.
(Updated, 2016 May 15). Diagnostic testing. Centers for Disease Control and Prevention. Available online at http://www.cdc.gov/zika/hc-providers/diagnostic.html. Accessed 5/17/2016.
(Updated 2016 May 15). Facts about microcephaly. Centers for Disease Control and Prevention. Available online at http://www.cdc.gov/ncbddd/birthdefects/microcephaly.html. Accessed 5/17/2016.
(April 1, 2016) Centers for Disease Control and Prevention. Update: Interim Guidance for Prevention of Sexual Transmission of Zika Virus — United States, 2016, MMWR 65(12);323–325. Available online at http://www.cdc.gov/mmwr/volumes/65/wr/mm6512e3.htm. Accessed June 2016.
(May 17, 2016) Centers for Disease Control and Prevention. Birth Defects, Facts about Microcephaly. Available online at http://www.cdc.gov/ncbddd/birthdefects/microcephaly.html. Accessed June 2016.
May 31, 2016, Centers for Disease Control and Prevention. Interim Guidance for Interpretation of Zika Virus Antibody Test Results. MMWR. Available online at http://www.cdc.gov/mmwr/volumes/65/wr/mm6521e1.htm?s_cid=mm6521e1_w. Accessed June 2016.
(August 16, 2016) AABB Association Bulletin #16-06. Blood Center and Public Health Actions to Reduce the Risk of Zika Virus Transfusion Transmission.
(August 26, 2016) FDA News Release. FDA advises testing for Zika virus in all donated blood and blood components in the US. Available online at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm518218.htm. Accessed December 2016.
(February 16, 2016) FDA News Release. FDA issues recommendations to reduce the risk for Zika virus blood transmission in the United States. Available online at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm486359.htm. Accessed December 2016.
(December 22, 2016) FDA Warns Health Care Providers Against Relying Solely on Zika Virus Serological IgM Assay Results; Reminds them to Wait for Confirmatory Test Results Before Making Patient Management Decisions. FDA Safety Communication. Available online at http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm534515.htm. Accessed January 10, 2017.